On December 9, 2021, the U.S. Food and Drug Administration (FDA) granted premarket approval to Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify patients with non-small cell lung cancer whose tumors carry epidermal growth factor receptor Exon20-insertion mutations for potential treatment with Rybrevant® (amivantamab-vmjw).
Read ThermoFisher Scientific's announcement.
Posted 12/10/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
